Article
Reactivation of the p90RSK-CDC25C Pathway Leads to Bypass of the Ganetespib-Induced G2-M Arrest and Mediates Acquired Resistance to Ganetespib in KRAS-Mutant NSCLC.
Molecular cancer therapeutics - 1 Aug 2017
Chatterjee Suman, Huang Eric H-B, Christie Ian, Burns Timothy F
Abstract excerpt
A subset of non-small cell lung cancers (NSCLC) are dependent upon oncogenic driver mutations, including the most frequently observed driver mutant KRAS, which is associated with a poor prognosis. As direct RAS targeting in the clinic has been unsuccessful to date, use of Hsp90 inhibitors appeared to be a promising therapy for KRAS-mutant NSCLC; however, limited clinical efficacy was observed due to rapid...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.